Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tolterodine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 9/20 | 1.00 |
| ▸ | CHRM2 known ✓ | P08172 | 3/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 3/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 2/20 | 1.00 |
| ▸ | HRH1 | P35367 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 1/20 | 1.00 |
| ▸ | KCNE1 | P15382 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | HRH2 | P25021 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | KCNQ1 | P51787 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 1/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tolterodine SCHEMBL29635996 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL3064 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL29379290 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL820421 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL36882 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL1260827 | 0.99 | CHRM3 (0.97) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL4840247 | 0.99 | CHRM3 (0.97) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL9221238 | 0.99 | CHRM3 (0.97) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL617185 | 0.99 | CHRM3 (0.97) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL1262758 | 0.99 | CHRM3 (0.97) | CHRM3CHRM2CHRM1CHRM5HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 737 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3104848-B1 | INHALABLE PARTICLE FORMULATIONS COMPRISING AN ANTIMUSCARINIC AGENT | CRYSTEC LTD (GB) | 2020-05-06 | — | — | EP | claimed |
| EP-2044001-B1 | PROCESS FOR PREPARATION OF 3-(2-HYDROXY-5-SUBSTITUTED PHENYL)-N-ALKYL-3-PHENYLPROPYLAMINES | LEK PHARMACEUTICALS (SI) | 2016-11-23 | — | — | EP | claimed |
| EP-1838659-B1 | PROCESS FOR PREPARATION OF N,N-DIISOPROPYL-3-(2-HYDROXY-5-METHYLPHENYL)-3-PHENYLPROPYLAMINE | LEK PHARMACEUTICALS (SI) | 2015-07-15 | — | — | EP | claimed |
| WO-2012098044-A1 | PROCESS FOR THE PREPARATION OF N,N-DIISOPROPYL-3-(2-HYDROXY-5-METHYLPHENYL)- 3-PHENYL PROPYLAMINE AND ITS SALTS STARTING FROM A NOVEL INTERMEDIATE | CAMBREX PROFARMACO MILANO S.R.L. (IT) | 2012-07-26 | — | — | WO | claimed |
| EP-2476665-A1 | Process for the preparation of N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)- 3-phenyl propylamine and its salts starting from a novel intermediate | Cambrex Profarmaco Milano S.r.l. (IT) | 2012-07-18 | — | — | EP | claimed |
| US-8193391-B2 | Process for preparation of 3-(2-hydroxy-5-substituted phenyl)-N-alkyl-3-phenylpropylamines | LEK PHARMACEUTICALS, D.D. (SI) | 2012-06-05 | — | — | US | claimed |
| US-20110171274-A1 | Fesoterodine Substantially Free of Dehydroxy Impurity | ACTAVIS GROUP PTC EHF (IS) | 2011-07-14 | — | — | US | claimed |
| EP-2323967-A2 | FESOTERODINE COMPRISING A REDUCED AMOUNT OF DEHYDROXYFESOTERODINE | Actavis Group PTC EHF (IS) | 2011-05-25 | — | — | EP | claimed |
| US-20100234473-A1 | PROCESS FOR PREPARATION OF 3-(2-HYDROXY-5-SUBSTITUTED PHENYL)-N-ALKYL-3-PHENYLPROPYLAMINES | LEK PHARMACEUTICALS D.D. (SI) | 2010-09-16 | — | — | US | claimed |
| WO-2010092500-A2 | A PROCESS FOR THE PREPARATION OF TOLTERODINE TARTRATE | ALEMBIC LIMITED (IN) | 2010-08-19 | — | — | WO | claimed |
| US-20040249211-A1 | PROCESS FOR THE PREPARATION OF TOLTERODINE | RANBAXY LABORATORIES LIMITED (IN) | 2004-12-09 | — | — | US | claimed |
| US-6822119-B1 | REACTING 3,4-DIHYDRO-6-METHYL-4-PHENYL-2H-BENZOPYRAN-2-ONE WITH DIMETHYL SULFATE USING PHASE TRANSFER CATALYST; DESTERIFICATION, REDUCTION, AMINATION, SULFONATION, DEPROTECTING, DECYCLIZATION, AND SALT FORMATION | RANBAXY LABORATORIES LIMITED (IN) | 2004-11-23 | — | — | US | claimed |
| EP-1434574-A2 | TOLTERODINE METABOLITES | Bridge Pharma, Inc. (US) | 2004-07-07 | — | — | EP | claimed |
| US-20030027856-A1 | Tolterodine metabolites | BRIDGE PHARMA, INC. | 2003-02-06 | — | — | US | claimed |
| WO-2003002059-A2 | TOLTERODINE METABOLITES | BRIDGE PHARMA, INC. (US) | 2003-01-09 | — | — | WO | claimed |
| JP-2664503-B2 | — | — | 1997-10-15 | — | — | JP | claimed |
| EP-0325571-B1 | NEW AMINES, THEIR USE AND PREPARATION | Kabi Pharmacia AB (SE) | 1991-08-07 | — | — | EP | claimed |
| EP-0354234-A1 | NEW AMINES, THEIR USE AND PREPARATION | KabiVitrum AB (SE) | 1990-02-14 | — | — | EP | claimed |
| WO-1989006644-A1 | NEW AMINES, THEIR USE AND PREPARATION | KABIVITRUM AB (SE) | 1989-07-27 | — | — | WO | claimed |
| EP-0325571-A1 | New amines, their use and preparation | Kabi Pharmacia AB (SE) | 1989-07-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234473-A1 | PROCESS FOR PREPARATION OF 3-(2-HYDROXY-5-SUBSTITUTED PHENYL)-N-ALKYL-3-PHENYLPROPYLAMINES | PAH, ALK, ALKBH3 | CHRM3 1118/4885CHRM2 1618/4885CHRM1 1237/4885 |
| US-20040249211-A1 | PROCESS FOR THE PREPARATION OF TOLTERODINE | ADRB3, ADRA1B, ADRA2B | CHRM3 74/4885CHRM2 162/4885CHRM1 788/4885 |
| US-20110171274-A1 | Fesoterodine Substantially Free of Dehydroxy Impurity | HSD17B7, CYP17A1, CYP21A2 | CHRM3 548/4885CHRM2 729/4885CHRM1 786/4885 |
| US-20030027856-A1 | Tolterodine metabolites | COMT, ADRB3, THOP1 | CHRM3 62/4885CHRM2 42/4885CHRM1 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.